Skip to main content

Table 4 B cell lymphoma antigens targeted by CAR-T cells

From: Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma

CAR-T antigen

Clinical study

Disease

CD19

Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma

B-cell lymphoma;

B-ALL

BAFF-R

Antitumor efficacy of BAFF-R targeting CAR T cells manufactured under clinic-ready conditions

B- ALL;

B-NHL

CD20

Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma

R/R DLBCL

CD22

CD19/CD22 Dual-Targeted CAR-T Therapy Active in Relapsed/Refractory DLBCL

R/R DLBCL

CD79b

Targeting CD79b for Chimeric Antigen Receptor T-Cell Therapy of B-Cell Lymphomas

B-cell lymphoma

CD37

Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma

R/R B-NHL

PD-1

CD19-Specific CAR-T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor is Effective in Patients with PD-L1 Positive B-Cell Lymphoma

PD-L1 Positive B-Cell Lymphoma

Igκ

T lymphocytes redirected against the κ light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells

Low-grade NHL;

B-CLL

  1. Abbreviations: CAR chimeric antigen receptor, B-ALL B-cell acute lymphoblastic leukemia, B-NHL B-cell non-Hodgkin lymphoma, R/R DLBCL relapsed and refractory diffuse large B cell lymphoma, PD-1 programmed cell death protein-1, PD-L1 programmed death ligand 1, B-CLL B-cell chronic lymphocytic leukemia